Kornimate/medical-research-clean huggingface dataset:
treatment of cancer-associated anorexia using megestrol acetate concentrated suspension

Conditions: Anorexia; Cachexia; Weight Loss

Summary: to compare the effect of megestrol acetate concentrated suspension and placebo on caloric intake in patients with cancer-associated anorexia.


Eligibility criteria:
inclusion criteria: * cancer of multiple types in stage ii, iii, or iv and not a candidate for chemotherapy; but may have been receiving radiation therapy * fair, poor, or very poor appetite * cancer-associated anorexia/cachexia (documented weight loss of 2% over the prior week, or at least 5% within past 30 days, or at least 7.5% over prior 3 months, or at least 10% over prior 6 months) * weight loss perceived to be associated with diminished appetite * eastern cooperative oncology group performance score of 0, 1, or 2 * life expectancy greater than 3 months * alert and mentally competent to complete study assessments * women of child-bearing potential required to use an adequate and reliable method of contraception. post-menopausal women have to have been so for at least 1 year * screening laboratory values must not be clinically significant (some exceptions per protocol) exclusion criteria: * brain, or head and neck tumors that may interfere with food consumption * aids-related wasting * radiation therapy to head and neck, abdomen, or pelvis within past 6 weeks, or for whom radiation therapy is anticipated during the study such that the result may interfere with food consumption * presence of conditions that interfere with oral intake or ability to swallow * absence of normally functioning gut * known mechanical obstruction of the alimentary or biliary tract, or malabsorption syndrome * intractable or frequent vomiting * clinically significant diarrhea * history of thromboembolic events, or on long-term anticoagulation for thromboembolism * uncontrolled diabetes mellitus, or symptomatic hypoadrenalism * poorly controlled hypertension or congestive heart failure * pregnant/lactating females, or planning on becoming pregnant * use of appetite stimulants within past 30 days * use of parenteral nutrition or tube feedings within past 1 week * chronic use of steroids within past 3 months (intermittent short-term use allowed) * current use of illicit substances * allergy, hypersensitivity, or other contraindication to megestrol acetate

Keywords: megestrol acetate anorexia cachexia cancer unintended weight loss body weight appetite megace es
combined sono-electro-magnetic therapy for treatment of refractory chronic pelvic pain syndrome

Conditions: Chronic Pelvic Pain Syndrome

Summary: treatment of chronic pelvic pain syndrome (cpps) is challenging for patients and physicians once conventional therapies fail. we hypothesize that combined sono-electro-magnetic therapy can improve refractory cpps in men. in addition, we postulate that combined sono-electro-magnetic therapy as well as placebo therapy has a significant effect on brain activity detectable by functional mri.


Eligibility criteria:
inclusion criteria: * cpss iii * symptomatic \>3 months * nih-cpsi total score =/\>15 * nih-cpsi pain =/\>8 exclusion criteria: * post void residual \>100ml * urinary tract infection * urethral stricture * prostate cancer * age \<18 years * claustrophobia * pacemaker, neurostimulator, insulin / pain pump

Keywords: chronic pelvic pain syndrome neuromodulation brain effects neuroimaging
chemotherapy for patients with non-small cell lung cancer who are non-smokers

Conditions: Non-small Cell Lung Cancer

Summary: the purpose of this study is to compare the efficacy and safety of chemotherapy followed sequentially by gefitinib versus chemotherapy alone in the first line treatment of non-small cell lung cancer (nsclc). this study will be conducted in asian patients who are classified as 'never smoker' since it is suggested that these patients are more likely to respond favorably to treatment with gefitinib.


Eligibility criteria:
inclusion criteria: * histologic or cytologic diagnosis non-small cell lung cancer (nsclc) (stage iiib or iv) * have not received any prior chemotherapy, molecular therapy, immunotherapy, biological therapy, or radiotherapy. exception: palliative radiotherapy that is completed at least 4 weeks prior to study enrolment. * have 'never smoked' (defined as having smoked \<100 cigarettes during his/her lifetime) * eastern cooperative oncology group (ecog) performance status 0 to 1 exclusion criteria: * concurrent administration of any other tumor therapy * other co-existing malignancies * pregnancy or breast feeding * serious concomitant disorders * inability or unwillingness to take folic acid or vitamin b12 supplementation
mobile health (m-health) intervention to reduce the epigenetic signature in metabolic syndrome (mets)

Conditions: Metabolic Syndrome; Obesity

Summary: the goal of this interventional study is to learn about the improvement in body composition effects of lifestyle intervention in subjects with metabolic syndrome. the main question it aims to answer is: does life style intervention lower body fat% and gene methylation levels in subjects with metabolic syndrome? participants will answer survey questions and get blood and body composition testing done at day 0, at 6 months and 12 months. keep a diary of their food and activity and the number of times they use mobile health application.

this is same as above.

Eligibility criteria:
inclusion criteria: 1. less than 5 kg body weight fluctuation in the 6 months prior to recruitment. 2. ideal body weight for height falling according to the south asian criteria as per who recommended i.e. body mass index (bmi) of 18.5 to 22.9 kg/m2 (normal-weight) and above 23kg/m2 (overweight/ obese). 3. any one of the following characteristics "according to the modified national cholesterol education program (ncep) atpiii guidelines i) waist circumference ii) hyper triglyceridemia (triglycerides ≥150 mg/dl) or low high density lipoprotein (hdl) cholesterol (hdl cholesterol ≤40 mg/dl for men and ≤50 mg/dl for women iii) elevated blood pressure (systolic blood pressure ≥130 mmhg and/or diastolic blood pressure ≥85 mmhg or current use of antihypertensive drugs) iv) impaired fasting glucose (fasting plasma glucose ≥100mg/dl) v) waist circumference (90 cm in men and 80 cm in women)". 4. have access to a smart phone/mobile and not using the fitness application exclusion criteria: 1. age \<18 or above 65 year 2. pregnant women 3. individuals with other comorbidities such as cancers, hepatic and/or renal impairment, or on hormonal supplements and/or anti-inflammatory drugs etc. 4. unfit for blood testing or no smart phone available
narrowband uvb for children with moderate to severe atopic eczema

Conditions: Moderate to Severe Atopic Eczema

Summary: to assess prospectively, the response of moderate to severe atopic eczema to a standard course of narrowband ultraviolet b phototherapy by using validated objective and subjective scoring systems.

children with moderate to severe atopic eczema prescribed a course of narrowband uvb phototherapy were scored (using validated scoring systems) objectively and subjectively before, during and after the course of treatment, as well as 3 and 6 months post treatment (to determine length of remission). their scores were compared to a control group. the control group comprised children with moderate to severe atopic eczema who were offered uvb but were unable to undertake the treatment.

Eligibility criteria:
inclusion criteria: * children aged 3-16 years with moderate to severe atopic eczema (as defined by the modified hannifin and rajka criteria) in whom there is a clinical indication for phototherapy (as deemed by their specialist dermatology consultant). exclusion criteria: * children under the age of 3 years or any child who lacks the maturity needed to stand in the phototherapy cabinet unsupervised. * mild disease (defined as a six area six sign atopic dermatitis (sassad) score \<10)

Keywords: atopic dermatitis
efficacy of ozone gel, doxycycline saturated chitosan dressing versus alveogyl

Conditions: Osteitis; Dry Socket

Summary: efficacy of ozone gel, doxycycline saturated chitosan dressing versus alveogyl in pain alleviation and healing of alveolar osteitis in diabetic patients


Eligibility criteria:
inclusion criteria: * patients over 20 years and under 60 years of age * dm controlled by medication, presented to outpatient clinic with signs and symptoms of dry socket * only participant that are willing to control and record blood glucose level throughout the study period exclusion criteria: * patients with any significant medical condition (besides dm) * alcoholic individuals * patients on drugs that affect the central nervous systems * patients who reported the use of drugs that might interfere with pain sensitivity * pregnant and lactating women * hypersensitivity to local anesthetics
development of a quality of life assessment tool for adult patients with a congenital heart disease, having had surgery during childhood

Conditions: Congenital Heart Disease

Summary: the mortality due to congenital heart diseases has decreased in recent decades, even for infants with the most complex lesions.therapeutic advances have prolonged the lifespan of people with these diseases. however, there are specific social and psychological troubles that appear later in life and can compromise employability, insurability and social integration. there are different types of congenital heart disease: those not operated in adulthood, and those operated for curative or palliative purposes. it is estimated that about 10 out of 1000 babies are born with a congenital cardiac malformation. one-third of these have a critical diagnosis requiring a surgical intervention. data from the literature show that there is an unusually high prevalence of psychosocial, neurological, developmental and psychiatric disabilities among survivors, as they enter formal education.there are many factors that influence developmental outcomes at school age. early intervention is an essential element in controlling these comorbidities. the continuous monitoring of the development by a multidisciplinary team would make it possible to identify a developmental disorder as soon as it appears and respond to it as quickly as possible.for many children and their families, the burden of the developmental consequences is higher than the daily impact of the heart disease. most studies and measures of quality of life in congenital heart patients require methodological improvements.they contribute little to the scientific basis of the quality of life in these patients. future quality of life studies must invest in rigorous conceptualization, adequate operational definition and a good measure of quality of life. the investigators propose to develop a reproducible and reliable quality of life measurement tool, suitable for adult patients suffering from congenital heart disease and having had surgery during childhood.


Eligibility criteria:
inclusion criteria: * congenital heart disease, * patients having had surgery during childhood, * patients followed within the chu brugmann hospital. exclusion criteria: * none.
e-health portal for individualized treatment monitoring and patient engagement in oncology research

Conditions: Breast Cancer Metastatic

Summary: evaluation of patient acceptance and characterization of response behaviour for web-based compared with respective paperbacked patient reported outcomes.

paperbacked ppro data from up to a total of 100 patients from the cohort of praegnant are planned to be included in the pepper i pro study. additionally 200 patients will be recruited in the web based epro cohort. the study duration per patient is at least 8 weeks. in cases of stable disease the study duration can be extended to up to 6 months with monthly pro assessments, according to the attached visit matrix, taking approximately 20 minutes per visit. the documentation at baseline should be performed during clinical routine with trained study personnel followed by remote self-reporting to minimize the patient effort. pepper i will be conducted as sub-protocol of the praegnant trial.

Eligibility criteria:
inclusion criteria: * patients enrolled in praegnant * women aged ≥18 years * patients with the diagnosis metastasized breast cancer undergoing any form of systemic therapy * patients who are willing and able to sign the informed consent form * patients with therapy change exclusion criteria: * patients who are not eligible for observation due to severe comorbidities or unavailability according to the treating physician * patients who are not able to handle a tablet computer or are unable to write * patients who are not able to understand the nature and extent of the trial and the procedures require
cardiopulmonary effects of prone position in cards

Conditions: ARDS Due to Disease Caused by SARS Co-V-2; Right Ventricular Dysfunction

Summary: in coronavirus disease-2019 (covid-19)-related ards (c-ards), especially in the severe form, increased shunt rate, impaired ventilation/perfusion ratio (v/q), hypoxic pulmonary vasoconstriction inhibition, and increased immune microthrombosis may have similar effects on the right ventricle .the cardiopulmonary pathophysiology and outcomes of c-ards vary, and this variability requires monitoring to follow the diagnosis and treatment process. this study aimed to increase the treatment success of the prone position in c-ards and to provide a prognostic factor for survival by analyzing and monitoring heart-lung interactions. therefore, we used transesophageal echocardiography (tee) to evaluate the cardiopulmonary effects of prone position.

this prospective study included 30 moderate-to-severe c-ards patients who were treated with prone position in the first 48 hours of invasive mechanical ventilation support. it was evaluated with transesophageal echocardiography three times: before prone position (pp) (t0), the first hour of pp (t1), and the first hour of returning to the supine position (t0 + 24 hours) (t2) after 23 hours prone position treatment. right ventricular end-diastolic area/left ventricular end-diastolic area (rveda/lveda) was preferred right ventricular evaluations as primer outcome. static compliance (c-stat) was examined in the evaluation of the pulmonary effect of prone position as secondary outcome.

Eligibility criteria:
inclusion criteria: * \>18 years * patients diagnosed with polymerase chain reaction/computed tomography results * moderate/severe severity class according to the berlin ards classification * prone position applied in the first 48 h after orotracheal intubation in treatment * obtaining an informed consent form exclusion criteria: * pulmonary embolism * pneumothorax * heart valve disease * pregnancy * perforated esophageal varices * coagulopathy * esophageal stricture * esophageal tumor * neck fracture * thrombocytopenia * gastrointestinal bleeding * previous stomach surgery * previous esophageal surgery * esophageal perforation

Keywords: transesophageal echocardiography cards heart lung interactions prone position right ventricle
image-hf: project iia canadian cardiomyopathy registry for device therapy

Conditions: Heart Failure

Summary: delayed enhanced mri in patients (of either ischemic or non-ischemic cause) being referred for primary prevention icd

device therapy using defibrillators and cardiac resynchronization therapy (crt) is an important advance in the care of patients with acquired heart disease and heart failure. in specific groups these devices appear to significantly reduce the risk of sudden cardiac death and progression of heart failure. however, our ability to identify ideal candidates, and those who are most likely to respond and benefit from this therapy, is poor. preliminary studies using specialized magnetic resonance imaging (mri) appears to be one of the more valuable ways of predicting response to device therapy and holds substantial promise for patients with cardiomyopathy. large, prospective registries are necessary to explore its real-world utility for risk prediction across a broad spectrum of patients. can-card mr is a national, multi-centre registry designed to address this particular need.

Eligibility criteria:
inclusion criteria: * .any patient accepted for primary prevention icd (+/-) crt) exclusion criteria: * known contra-indications to mri. * recent myocardial infarction or revascularization procedure within the past 3 months. * gfr (glomerular filtration rate) ≤ 30 ml. / min/ m2.
optimization of the preservation of muscle mass and / or its recovery by a protein-energy chrononutrition approach dissociated from meals

Conditions: Undernutrition

Summary: muscle wasting has a multifactorial origin, including decreased physical activity, malnutrition, loss of post-incident muscle recovery abilities, and decreased ability to regenerate muscle. among the strategies tested to improve the production of proteins and thus muscle is the supplementation of whey proteins. however this strategy does not seem sufficient and optimal to avoid muscle wasting and it must be complemented by a complementary action. muscle protein degradation also occurs during the nocturnal fasting periods to provide amino acids for energy purposes and to produce glucose, essential for vital organs. the preservation of the benefit of whey intake during meals could therefore be optimized by reducing the use of muscle proteins for energy purposes during the night.

in this study, three arms will be studied for 3 months: 1 control group, 1 group with whey supplementation at lunch, and 1 group with whey supplementation at lunch and an energy bolus before bedtime. actions include weight and body composition monitoring, nutritional status and muscle function, as well as mechanistic.

Eligibility criteria:
inclusion criteria: * resident on the accommodation establishments for dependent elderly persons on the mutuality of loire, france * risk of undernutrition or moderate undernutrition with one of the following criteria : * either 5-10% of weight loss in 1 month or 10-15% in 6 months. * or body mass index (bmi) between 16 and 21 * or albumin levels between 30 and 35 g/l * or global mini nutritional assessment (mna) test between 17 and 23.5 * or short emergency geriatric assessment (sega) score \>8 exclusion criteria: * sub-acute pathology (flu, gastroenteritis, bacterial infections ...) or trauma (fracture, surgery ...) in the 30 days prior to inclusion. * hepatocellular insufficiency * heart failure with decompensation * severe dementia, * insulin-treated diabetes * renal insufficiency (clearance \<30 ml / min) * long-term cortico-therapy * cancer undergoing chemotherapy treatment or/and radiotherapy * gastrointestinal pathology, * diet incompatible with the nutritional protocol (intolerance to milk or lactose, vegetarians, vegans, ...) * motor disability leading to the impossibility of doing muscle function tests.

Keywords: malnutrition undernutrition elderly protein carbohydrate
weight loss following an episode of pre-eclampsia using a dissociated or hypocaloric diet in overweight or obese patients

Conditions: Pre-Eclampsia; Obesity

Summary: in view of the known link between pre-eclampsia, overweight/obesity and chronic kidney disease, the aim is to offer for obese and overweight patients to reduce their bmi without reducing lean body mass. the popadipe project will make it possible to limit overweight or obesity by means of nutritional management chosen by the patient (hypocaloric or a dissociated diet). the latter has been the subject of little scientific investigation, particularly in relation to the management of post-pre-eclampsia.


Eligibility criteria:
inclusion criteria: * person affiliated to social security * free, informed and written consent signed by the participant and the investigator (no later than the day of day of inclusion and before any examination required by the research) * patient over 18 years of age at the time of inclusion and \< 45 years of age * having had an pre-eclampsia in the last 5 years according to the definitions of the isshp 2018 * patient with a bmi between 25 kg/m² and 40 kg/m² who accepts dietetic follow up * patient with a medical prescription for dietetic follow-up aimed at losing weight loss * patient with a balanced diet exclusion criteria: * patients with a mental disability or language barrier that prevents them from understanding or consenting to the study * patients deprived of their liberty by judicial or administrative decision * patients under psychiatric care * patients subject to a legal protection measure * patients with cognitive disorders or defined eating disorders * patients who are pregnant or breast-feeding * patients undergoing steroid treatment and/or immunosuppression * have been on a low-calorie or dissociated diet for at least 6 months * patients with ckd stage ≥ 3a

Keywords: pre-eclampsia obesity dissociated diet
resuscitation outcomes in the netherlands flashmob questionnaire

Conditions: Cardiopulmonary Arrest; DNR-orders

Summary: the aim of this study is to gain insight in patients' experiences regarding do not resuscitate conversations and decisions. a multicentre flash mob investigation will be conducted in which data will be obtained over the course of two weeks using electronic questionnaires that patients will fill out. general demographic data and a brief quality of life assessment (eq-5d) will be collected. whether a dnr converstation has taken place will be noted, along with patients' experiences with this conversation. lastly the patient will be asked about his/her expectations of survival after cardiopulmonary resuscitation.

rationale: in-hospital cardiac arrest, associated with a survival to discharge of 15.0%, results in a good neurologic discharge in 9.1% - 30.0% of patients. therefore it is recommended to engage in advanced care planning with patients, to discuss do-not-resuscitate (dnr) directives. in current knowledge, there are no published data about the prevalence of these dnr orders and associated factors in hospitalized patients in the netherlands. also, the conversation about dnr are sometimes perceived as awkward or untimely by patients. objective: the primary goal is to estimate prevalence dnr order in dutch hospitals. a secondary goal is to assess what geographical, patient and disease factors are associated with dnr status. furthermore patient experience in the conversation leading to dnr-orders is of interest. study design: a cross-sectional point prevalence study, in 10 participating hospitals of the routine project. study population: patients who plan to be admitted for more than 24 hours to the participating hospitals, aged 18 or older, who are responsive and conscious. main study parameters/endpoints: the prevalence of dnr orders, expressed as number per 1000 beds. nature and extent of the burden and risks associated with participation, benefit and group relatedness: there is no risk. only one ten-minute interview per participant. therefore the benefit of this study (as described in the objectives) outweigh the potential risks.

Eligibility criteria:
inclusion criteria: * all patients admitted to the participating hospitals with a planned admission \>24 hours at the moment this study takes place. exclusion criteria: * • refusal to participate * \<18 years of age * admitted in outpatient clinic and day treatment centres (e.g. haemodialysis) * admitted \<24 hours, as defined by not sleeping overnight in hospital * no reliable proxy in the following situations: * unable to answer questions (e.g. unconscious, cognitively impaired, delirious) * language barrier (with no interpreter or family member) * the following hospital departments are excluded: * intensive care unit * coronary/acute cardiac care unit * obstetrics * paediatrics * stroke unit * dialysis (outpatient dialysis) * day-care wards/short-stay (i.e. \<1 day) * palliative care